Clinical trials: Hidradenitis
Hidradenitis Suppurativa (Acne Inversa)
HS ABSCESSES: I&D VS PUNCH DEBRIDEMENT
This randomized-control trial is designed to determine the recurrence rate of HS abscesses following drainage via two methods: I\&D with a linear incision and PD with an 8mm punch biopsy.
- Trial name
- HSPUNCH (NCT06731309)
- Testing
- Punch Debridement, Incision and Drainage
- Where
- Netherlands
- Volunteers
- 72 people
- Sponsor
- Erasmus Medical Center
Vitiligo, Atopic Dermatitis
An Observational Study of Patients With Dermatologic Disease
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients.
- Conditions
- Vitiligo, Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa (HS)
- Trial name
- TARGET-DERM+ (NCT07748169)
- Where
- United States
- Volunteers
- 2,000,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Hidradenitis Suppurativa
Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository
Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition.
- Trial name
- HS PROGRESS (NCT04115566)
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- University of California, San Francisco
Hidradenitis Suppurativa
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.
- Trial name
- NCT06768671
- Testing
- Sonelokimab
- Where
- 18 sites in United States
- Volunteers
- 35 people
- Sponsor
- MoonLake Immunotherapeutics AG
Acne, Acne Vulgaris
A Pilot Study to Explore the Role of Gut Flora in Acne
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Acne, Acne Vulgaris, Acne Keloidalis, Acne Keloid
- Trial name
- NCT04214483
- Testing
- No intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Hidradenitis Suppurativa (Acne Inversa)
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
This is a randomized, double blind, multicenter study in patients with moderate to severe chronic hidradenitis suppurativa in parallel groups, to determine the efficacy and safety of multiple doses of CJM112 in comparison to…
- Trial name
- NCT02421172
- Testing
- CJM112
- Where
- 16 sites in United States, Denmark and 3 more
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa
A study to assess the safety and efficacy of the IV drug infliximab for the treatment of hidradenitis suppurativa
- Trial name
- HS2006 (NCT00795574)
- Testing
- infliximab
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Florida Academic Dermatology Centers
Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa)
Global Healthcare Study on Hidradenitis Suppurativa
The Global Healthcare Study on Hidradenitis Suppurativa (GHSHS) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity…
- Trial name
- GHSHS (NCT07659769)
- Where
- Switzerland
- Volunteers
- 9,600 people
- Sponsor
- Julia Tatjana Maul
Hidradenitis Suppurativa, Wide Excision
Quality of Life After Wide Surgical Excision in Patients With Hidradenitis Suppurativa
Patients undergoing wide surgical excision of their hidradenitis suppurativa areas are asked by telephone about their quality of life by standard questionnaires (WHOQOL-BREF, DLQI, Skindex, MHF, FLQA-d) and their sexual function…
- Trial name
- NCT02593604
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- University Hospital Schleswig-Holstein
Hidradenitis Suppurativa
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.
- Trial name
- NCT07049575
- Testing
- Ruxolitinib Cream
- Where
- 21 sites in United States
- Volunteers
- 24 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa (HS)
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.
- Trial name
- NCT07213973
- Testing
- Povorcitinib
- Where
- 30 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- Incyte Corporation
Down Syndrome, Alopecia Areata
Tofacitinib for Immune Skin Conditions in Down Syndrome
People with Down syndrome (DS) display widespread immune dysregulation, including several immune skin conditions. This study hypothesizes that pharmacological inhibition of the increased interferon (IFN) signaling seen in DS is…
- Conditions
- Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema, Hidradenitis Suppurativa
- Trial name
- NCT04246372
- Testing
- Tofacitinib
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Colorado, Denver
Hidradenitis Suppurativa
The Ohio State University Dermatology Biorepository
This study will create and extend a source of clinical specimens for the future study of inflammatory skin disorders.
- Trial name
- NCT03146676
- Where
- United States
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Hidradenitis Suppurativa, Pediatric Plaque Psoriasis
Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea
- Conditions
- Hidradenitis Suppurativa, Pediatric Plaque Psoriasis, Juvenile Idiopathic Arthritis
- Trial name
- NCT07243782
- Testing
- Secukinumab
- Where
- South Korea
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals